Industry Network

CCRM’s founding industry consortium represents key sectors of the regenerative medicine industry – pharmaceutical, devices, reagents, tools, biomaterials and cell and gene therapies. The industry consortium consists of large multinationals, small-medium enterprises (SME) and emerging biotechnology companies. It provides market knowledge and a ready supply of global receptors for technologies and products generated by CCRM and its partners.

CCRM Industry Partnership Evolution: Structure, Optimize & Enhance Partner Engagement

Why Now?

CCRM’s investments in process development, manufacturing and company creation are driving the need for an expanded engagement model with our industry network.

CCRM’s engagement framework consists of four levels, with increasing amounts of engagement from the first level to the fourth.The first level is Ecosystem Partner, which consists of over 200 regenerative medicine companies in CCRM’s network.

The second level is Spotlight Partner. These companies have active and committed business relationships with CCRM.

The third level is Premier Partner. This group consists of strong technology and business collaborators aligned with CCRM’s vision.

The fourth level is Anchor Partner, which consists of strategic and financial partners in CCRM’s core initiatives.

Industry Anchor Partners: a select group of major industry/ecosystem players engaged with CCRM to accomplish the shared goal of building new capabilities and/or infrastructure that will benefit the regenerative medicine ecosystem. Our goals for engagement with anchor partners are to drive forward critical projects, tell the story of our success to the broader community, and create a long-term plan for continued partnership. Cytiva is CCRM’s main industry anchor partner. Cytiva is CCRM’s leading technology development partner, committing $20M to seed the Centre for Advanced Therapeutic Cell Technologies (CATCT) and later providing an additional $15M. This partnership has established product and process development capabilities that serve a critical need in the regenerative medicine ecosystem. OmniaBio Inc., a subsidiary of CCRM, was first announced in March 2022 and celebrated the beginning of construction in October 2022. It will be Canada’s largest CDMO for cell and gene therapies, enabling Phase I to commercial-scale manufacturing of gene-modified cells and viral vectors. OmniaBio will catalyze life sciences jobs and innovation in Ontario.

Industry Premier Partners: companies actively engaged with CCRM in significant contract service work for product and process development and/or manufacturing, as well as companies in which CCRM currently holds equity stakes. Our goals for engagement with premier partners are to deliver high-quality, reputation-building services, explore new ways our commercialization platform can grow their business by better understanding their needs, and partner for the advancement of new therapies/tools.

Industry Spotlight Partners: companies that maintain a business relationship with CCRM by sponsoring our events (e.g. annual Till and McCulloch Meetings), engaging in contract service work or partnering on critical projects to support the broader community. Our goals for engagement with spotlight partners are to offer high-quality services, look for opportunities to increase engagement, and provide increased visibility for these companies in the regenerative medicine ecosystem.

Industry Ecosystem Partners: a diverse and expanding cohort of companies who are interested in learning about regenerative medicine and finding opportunities to boost interactions within the community. Our goals for engagement with ecosystem partners are to stay connected, provide information about CCRM’s activities and others within the community, and facilitate engagement with the broader regenerative medicine ecosystem.